Novavax Inc (NVAX) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Novavax inc   (NASDAQ: NVAX)
 

Novavax Inc Growth Comparisons

Select each growth Category to receive further Information





NVAX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) -3.05 % 5.15 % 10.2 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 20.46 % -11.92 % -2.54 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) -61.33 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) -0.52 % 1.16 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 18.76 % 8.24 % 8.67 % 13.63 %


NVAX's Growth Comparisons in III. Quarter 2026




Although the Biotechnology & Pharmaceuticals industry saw advancing Revenue by 5.15%, Novavax Inc announced -3.05% year on year sales decline in the third quarter 2026, to $ 68 millions, and underperformed the 10.2% Revenue improvement in the Healthcare sector. Weak third quarter sales, in Biotechnology & Pharmaceuticals industry and within the Healthcare sector, were reflected in Novavax Inc results which underperformed overall market.

Company's sequential top-line increase was 20.46% from the second quarter. Average annual sales rise for Novavax Inc is 18.76%, while S & P 500's average yearly sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 Results.

NVAX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
CIC Product-Related Development Milestones
-
-
Total
-3.05 %
20.46 %


Growth Rates of NVAX's Income in the third quarter 2026


NVAX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 524.46 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) - -49.25 % -12.31 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) - 996.91 % 31.01 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) - 229.96 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change - -18.52 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - -80.67 % -38.84 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - - -63.29 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -86.3 % 9.9 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) - -58.35 % -4.66 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -11.53 % 8.91 % -28.64 %

NVAX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - -82.09 % -39.18 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) - -89.11 % 11.48 % 27.07 %
Y / Y Net Income Change (Q3 TTM) - 102.98 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) - -7.86 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth - -8.71 % 9.09 % 23.95 %

NVAX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - -83.01 % -38.84 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - - -63.29 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) - - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - 38.46 % 8.91 % -28.64 %



NVAX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - -84.26 % -39.18 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) - -89.98 % 11.48 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) - - 10.56 % 4.93 %
EPS Net 5 Year Avg. Change - -8.71 % 9.09 % 23.95 %



Novavax Inc reported bottom-line of $ -0.19 in the third quarter, compare to $ -1.25 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry fell by -84.26%, while Healthcare sector decreased by -39.18%, and overall market improved by 90.69%.

The company's sequential bottom-line increase was 20.46% from the second quarter. Average annual income per share rise for Novavax Inc is 18.76%, while S & P 500's average yearly income per share growth is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings results.

NVAX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - - 44.7 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) - -53.34 % -42.72 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) - 12.58 % 19.45 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) - 17.87 % 5.9 % 15.75 %
Free Cash Flow 5 Year Avg. Change - -13.84 % 0.41 % 1.79 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - 31.48 % - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - 783.99 % - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 23.25 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -49.38 % 31.05 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 73.64 % -4.21 % -19.33 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -19.76 % 3.16 % 8.85 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -16.26 % 6.45 % 0.98 % 23.05 %
Capital Expenditures 5 Year Avg. Change -34.9 % 9.66 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.